A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT

NCT06491719 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome
EBV
Hemophagocytic Lymphohistiocytoses

Interventions

OTHER: NCR300（Allogenic Ipsc-derived Natural Killer cells ）

Sponsor

Beijing Friendship Hospital